Codexis, Inc. (NASDAQ:CDXS) Short Interest Update

Codexis, Inc. (NASDAQ:CDXS) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,290,000 shares, an increase of 20.5% from the December 15th total of 1,900,000 shares. Based on an average trading volume of 668,900 shares, the short-interest ratio is presently 3.4 days.

Analyst Ratings Changes

A number of brokerages recently issued reports on CDXS. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Codexis in a research report on Friday, November 22nd. Benchmark restated a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Hedge Funds Weigh In On Codexis

Hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new stake in shares of Codexis in the third quarter valued at approximately $66,000. Marshall Wace LLP purchased a new stake in shares of Codexis in the 2nd quarter worth $89,000. Algert Global LLC grew its position in shares of Codexis by 17.1% during the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after buying an additional 6,069 shares in the last quarter. Jackson Square Capital LLC purchased a new position in shares of Codexis during the fourth quarter valued at $210,000. Finally, Squarepoint Ops LLC raised its holdings in shares of Codexis by 113.8% in the second quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 39,664 shares in the last quarter. 78.54% of the stock is currently owned by institutional investors.

Codexis Trading Up 1.6 %

Shares of CDXS stock traded up $0.08 on Friday, reaching $5.00. 638,754 shares of the company’s stock were exchanged, compared to its average volume of 695,149. The company’s fifty day simple moving average is $4.80 and its 200 day simple moving average is $3.73. Codexis has a 52 week low of $2.53 and a 52 week high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $406.90 million, a PE ratio of -5.75 and a beta of 2.13.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The business had revenue of $12.83 million for the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same quarter last year, the business posted ($0.26) earnings per share. As a group, analysts forecast that Codexis will post -0.77 EPS for the current year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.